SYDNEY, July 28 (Bernama-GLOBE NEWSWIRE) — George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program PrOSPeCT–a program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products.
Omico is an Australian government-backed national network of leading researchers, clinicians and industry partners, including George Clinical, that are using precision medicine to unlock new potential in Australian research and turn the tide on cancer. With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment across the entire nation, Omico is accelerating access to next-generation treatments and preventive strategies improving outcomes for all Australians affected by cancer.